Richard Festenstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10819322/publications.pdf

Version: 2024-02-01

430874 677142 1,950 22 18 22 citations h-index g-index papers 31 31 31 2355 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Modulation of Heterochromatin Protein 1 Dynamics in Primary Mammalian Cells. Science, 2003, 299, 719-721.	12.6	265
2	DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature, 2003, 422, 909-913.	27.8	244
3	Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends in Genetics, 2002, 18, 252-258.	6.7	232
4	Locus control regions: overcoming heterochromatin-induced gene inactivation in mammals. Current Opinion in Genetics and Development, 1997, 7, 614-619.	3.3	147
5	Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet, The, 2014, 384, 504-513.	13.7	129
6	Heterochromatin protein 1 modifies mammalian PEV in a dose- and chromosomal-context-Âdependent manner. Nature Genetics, 1999, 23, 457-461.	21.4	121
7	Sexual Dimorphism in Mammalian Autosomal Gene Regulation Is Determined Not Only by Sry but by Sex Chromosome Complement As Well. Developmental Cell, 2010, 19, 477-484.	7.0	111
8	Evidence for Distinct CD4 Silencer Functions at Different Stages of Thymocyte Differentiation. Molecular Cell, 2002, 10, 1083-1096.	9.7	109
9	Heritable gene silencing in lymphocytes delays chromatid resolution without affecting the timing of DNA replication. Nature Cell Biology, 2003, 5, 668-674.	10.3	91
10	Locus control regions and epigenetic chromatin modifiers. Current Opinion in Genetics and Development, 2000, 10, 199-203.	3.3	78
11	Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. Human Molecular Genetics, 2013, 22, 2662-2675.	2.9	71
12	Human HMG box transcription factor HBP1: a role in hCD2 LCR function. EMBO Journal, 1999, 18, 6396-6406.	7.8	58
13	Transcription Elongation and Tissue-Specific Somatic CAG Instability. PLoS Genetics, 2012, 8, e1003051.	3.5	56
14	Gene regulation and epigenetics in Friedreich's ataxia. Journal of Neurochemistry, 2013, 126, 21-42.	3.9	49
15	Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer's disease mouse model. Molecular Psychiatry, 2021, 26, 5669-5689.	7.9	47
16	Identification of a novel distal regulatory element of the humanNeuroglobingene by the chromosome conformation capture approach. Nucleic Acids Research, 2017, 45, 115-126.	14.5	36
17	Epigenetics and Triplet-Repeat Neurological Diseases. Frontiers in Neurology, 2015, 6, 262.	2.4	32
18	Breaking the silence in Friedreich's ataxia. , 2006, 2, 512-513.		23

#	Article	IF	CITATIONS
19	The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigenetics and Chromatin, 2009, 2, 14.	3.9	21
20	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 2019, 1, 33.	2.0	14
21	Transcriptional Activation of Pericentromeric Satellite Repeats and Disruption of Centromeric Clustering upon Proteasome Inhibition. PLoS ONE, 2016, 11, e0165873.	2.5	6
22	Context is everything: activators can also repress. Nature Structural and Molecular Biology, 2012, 19, 973-975.	8.2	2